For the first time in ∼5 years, biotech and pharmaceutical patenting picked up slightly as a share of total patents. In 2005, 23 out every 1,000 US patent specifications refer to 'nucleic acid,' and 43 out of 1,000 reference 'pharmaceutical.' Almost 6,000 biotech patents were awarded by the European Patent Office in 2002; relative share of biotech intellectual property (IP) has grown strongly in New Zealand, Norway and Chinese Tapei, but has diminished in Austria, Italy, Finland, Belgium and Ireland.
Rights and permissions
About this article
Cite this article
Lawrence, S. Biotech patenting upturn. Nat Biotechnol 24, 1190 (2006). https://doi.org/10.1038/nbt1006-1190
Issue Date:
DOI: https://doi.org/10.1038/nbt1006-1190
This article is cited by
-
An assessment of emerging molecular farming activities based on patent analysis (2002∼2006)
Biotechnology and Bioprocess Engineering (2008)
-
Challenges for Australia's Bio/Nanopharma Policies: trade deals, public goods and reference pricing in sustainable industrial renewal
Australia and New Zealand Health Policy (2007)
